Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ilorasertib in CDKN2A-deficient advanced solid cancers
NCT02478320Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ilorasertib in solid tumor (advanced stage), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2016; status: terminated.
02
Drugs
ilorasertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02478320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02478320.